Review



ipa3  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Santa Cruz Biotechnology ipa3
    Ipa3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ipa3/IPA+3/pmc03578113-108-1-10
    Average 90 stars, based on 11 article reviews
    ipa3 - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Indirect Immunoperoxidase Assay:

    Article Title: Rapid Estrogen and Progesterone Signaling to Dendritic Spine Formation via Cortactin/Wave1-Arp2/3 Complex.
    Article Snippet: .. Progesterone, 17β-estradiol and Forskolin (1 μM) were from Sigma-Aldrich; PP2 (Src inhibitor, 10μM) and Roscovitine3 (Cdk5 inhibitor, 50μM) were from Calbiochem; FAK inhibitor (FAKi, (1 μM), IPA-3 (PAK1 inhibitor, 10μM) and CK-666 (Arp2/3 complex inhibitor, 4μM) were from Santa Cruz Biotechnology. .. ICI 182,780 (100 nM) was obtained from Tocris Cookson (Avonmouth, UK).

    Article Title: Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer.
    Article Snippet: Purpose Heregulin (HRG) signaling has been implicated in the development of an aggressive phenotype in breast cancer (BC) cells, and HER2 overexpression has been associated with a worse prognosis in BC patients.. Nevertheless, the molecular mechanisms through which HRG affects the efficiency of anti-HER2 therapies such as trastuzumab (Tz) and trastuzumabemtansine (T-DM1) are currently unknown.. Methods In the present study, we evaluate the molecular action of HRG toward fundamental scaffold proteins and several kinases in the signal transduction pathways triggered via HER2/HER3, which integrate precise and sequential steps to promote changes in cell morphology to impulse BC cell migration.

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Recombinant:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Clinical Proteomics:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    MTT Assay:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Sterility:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Polymerase Chain Reaction:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Cloning:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Mutagenesis:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    shRNA:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Plasmid Preparation:

    Article Title: PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 .. REAGENT or RESOURCE SOURCE IDENTIFIER Chemicals, Peptides, and Recombinant Proteins Recombinant Human TGF-b1 R&D Systems Cat. # 240-B-002 PAK4i (CRTDL4) Cancer Research Technology N/A IPA-3 Santa Cruz Biotechnology Cat. # sc-204016 Akt inhibitor Fibronectin from bovine plasma 0.1% solution Sigma Cat. # F1141 Fibronectin HiLyte 488 Cytoskeleton, Inc. Cat. # FNR02-A Human M-CSF Miltenyi Biotec Cat. # 103-093-963 MTT reagent Sigma Cat. # M5655 DMSO, sterile filtered Sigma Cat. # D2438 MCP-1 (CCL2) R&D Systems Cat. # 279-MC-010 Critical Commercial Assays Zero Blunt PCR Cloning Kit Invitrogen Cat. # K2700-20 QuikChange XL Site-Directed Mutagenesis Kit Stratagene Cat. # 200516 15ml Lymphoprep Axis-Shield Cat. # 1114544 CD14 Microbeads, human Miltenyi Biotec Cat. # 103-050-201 Experimental Models: Cell Lines THP-1 cells ATCC TIB-202 HEK293T cells ATCC CRL-3216 Oligonucleotides Cloning primer: PAK4 shRNA 2 FWD: CCGGGGTGAACATGTATG AGTGCTCGAGCACTCATACATGTTCACCTTTTTG This paper N/A Cloning primer: PAK4 shRNA 2 REV: AATTCAAAAAGGTGAACATG TATGAGTGCTCGAGCACTCATACATGTTCACC This paper N/A Cloning primer: PAK4 shRNA 3 FWD: CCGGCTTCGGACATTCATG ATCGCTCGAGCGATCATGAATGTCCGAAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 3 REV: AATTCAAAAACTTCGGACAT TCATGATCGCTCGAGCGATCATGAATGTCCGAAG This paper N/A Cloning primer: PAK4 shRNA 4 FWD: CCGGCTGCTGGACGAGTT TGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAGTTTTTG This paper N/A Cloning primer: PAK4 shRNA 4 REV: AATTCAAAAACTGCTGGAC GAGTTTGAGAACCTCGAGGTTCTCAAACTCGTCCAGCAG This paper N/A SDM primer: PAK4 shRNA 4 rescue FWD: GCCCTCACGCTGCTC CTCGATGAGTTCGAGAACATGTC This paper N/A SDM primer: PAK4 shRNA 4 rescue REV: GACATGTTCTCGAACT CATCGAGGAGCAGCGTGAGGGC This paper N/A SDM primer: PAK4r(K350,351M) FWD: CTGGTGGCCGTCATGAT GATGGACCTGCGC Wells laboratory N/A SDM primer: PAK4r(K350,351M) REV: GCGCAGGTCCATCATCAT GACGGCCACCAG Wells laboratory N/A See Table S1 for more details of oligonucleotides used in this study Recombinant DNA pHR’SINcPPT-SFFV (pLNT-SffV) Jones laboratory; Vijayakumar et al., 2015 N/A pLKO.1 Addgene; Moffat et al., 2006 Addgene Plasmid 10878 pCMVDR8.91 Jones laboratory N/A pMD.G Jones laboratory N/A pDEST27-PAK4 Wells laboratory N/A pLNT/SffV-EGFP-PAK4 This paper N/A pLNT/SffV-EGFP-PAK4(rescue) This paper N/A (Continued on next page) Cell Reports 29, 3385–3393.e1–e6, December 10, 2019 e2 ..

    Incubation:

    Article Title: Synthesis, biological evaluation and toxicity of novel tetrandrine analogues
    Article Snippet: On the following day, cells were transfected with either pcDNA3-CYP3A4-EGFP or pcDNA3EGFP using the LipofectamineTM 3000 (Invitrogen, Waltham, USA) transfection reagent according to the manufacturer’s instructions. .. On the subsequent day, cells were incubated with luciferin-IPA (3 mM) in the presence or absence of ketoconazole (Santa Cruz biotechnology, Dallas, USA) (10 mM) for 60 min. Luminescence was detected using the nonlytic method as described by the manufacturer. .. Isolation of mRNA (RNeasy Mini Kit, QIAGEN, Venlo, Netherlands), synthesis of cDNA templates (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Waltham, USA) and quantitative real-time PCR (ABI 7300 Real-Time PCR System, Applied Biosystems) with human actin serving as housekeeping gene were performed as described before [58].

    Article Title: Synthesis, biological evaluation and toxicity of novel tetrandrine analogues
    Article Snippet: On the following day, cells were transfected with either pcDNA3-CYP3A4-EGFP or pcDNA3-EGFP using the LipofectamineTM 3000 (Invitrogen, Waltham, USA) transfection reagent according to the manufacturer’s instructions. .. On the subsequent day, cells were incubated with luciferin-IPA (3 μM) in the presence or absence of ketoconazole (Santa Cruz biotechnology, Dallas, USA) (10 μM) for 60 min. Luminescence was detected using the nonlytic method as described by the manufacturer. .. Isolation of mRNA (RNeasy Mini Kit, QIAGEN, Venlo, Netherlands), synthesis of cDNA templates (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Waltham, USA) and quantitative real-time PCR (ABI 7300 Real-Time PCR System, Applied Biosystems) with human actin serving as housekeeping gene were performed as described before [ ].



    Similar Products

    94
    MedChemExpress ipa3
    Ipa3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ipa3/IPA-3/pmc12020991-217-7-12
    Average 94 stars, based on 1 article reviews
    ipa3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    ipa3  (Tocris)
    93
    Tocris ipa3
    Ipa3, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ipa3/IPA+3/pm41249054-59-5-11
    Average 93 stars, based on 1 article reviews
    ipa3 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Selleck Chemicals ipa3
    GNAQ- and GNA11-mutant uveal melanoma cells are sensitive to PAK inhibitors. ( A ). The indicated concentrations of a pan-PAK inhibitor PF3758309 were added to the cultures of 92.1, Mel202 and MP41 uveal melanoma cells. Five days later, cell numbers were compared using the methylene blue staining and extraction method. The values for each cell line were normalized to those in the respective control cultures. Error bars denote standard deviations of quadruplicates. ( B ). 92.1, Mel202 and MP41 uveal melanoma cells were treated with a group I PAK inhibitor <t>IPA3</t> and the results were analyzed as in A. Half-maximal inhibitory concentrations (IC50) with corresponding 95% confidence intervals (95% CI) are shown.
    Ipa3, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ipa3/IPA-3/pmc12564536-50-0-4
    Average 94 stars, based on 1 article reviews
    ipa3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Selleck Chemicals pak1 inhibitor ipa3
    GNAQ- and GNA11-mutant uveal melanoma cells are sensitive to PAK inhibitors. ( A ). The indicated concentrations of a pan-PAK inhibitor PF3758309 were added to the cultures of 92.1, Mel202 and MP41 uveal melanoma cells. Five days later, cell numbers were compared using the methylene blue staining and extraction method. The values for each cell line were normalized to those in the respective control cultures. Error bars denote standard deviations of quadruplicates. ( B ). 92.1, Mel202 and MP41 uveal melanoma cells were treated with a group I PAK inhibitor <t>IPA3</t> and the results were analyzed as in A. Half-maximal inhibitory concentrations (IC50) with corresponding 95% confidence intervals (95% CI) are shown.
    Pak1 Inhibitor Ipa3, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ipa3/IPA-3/pm40262669-93-25-28
    Average 94 stars, based on 1 article reviews
    pak1 inhibitor ipa3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    Millipore ipa3
    Effects of inhibiting vimentin S38 phosphorylation on metastasis. A HeLa cells were suspended for 2 h in the presence of varying concentrations of <t>IPA3</t> as indicated, and Ser38 phosphorylation of vimentin was measured as in Fig. A. B HeLa cells suspended for 2 h in the presence or absence of 40 μM IPA3 were analyzed for surface integrin β1 by using flow cytometry. C The mean fluorescence intensities of integrin β1 staining in each condition were normalized against the untreated control and presented as a one-dimensional scatter plot. *, p < 0.05 (paired T test, n = 3). D HeLa and HeLa_VIMKO cells suspended for 24 h in the presence or absence of 40 μM IPA3 were analyzed by flow cytometry as in Fig. A. E Percentages of PI-positive cells in ( D ) are shown. ***, p < 0.0001, n.s.: not significant (one-way ANOVA followed by Tukey multiple-comparison test, n = 3). F Schematic of an in vivo experiment using BLAB/c mice. 1 × 10. cells of 4T1 were injected into the tail vein, and 5 mg/kg IPA3 or DMSO were treated through intraperitoneal injection every day for 14 days. G Representative pictures of lungs from mice treated with control vehicle (top) or IPA3 (bottom) are shown. H The number of metastatic nodules in the lungs in each group was counted and presented as a graph. ***, p < 0.0001 (unpaired T test, n = 5 for each group)
    Ipa3, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ipa3/ipa+3/pmc11197373-215-34-35
    Average 90 stars, based on 1 article reviews
    ipa3 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    94
    MedChemExpress ipa-3
    Effects of inhibiting vimentin S38 phosphorylation on metastasis. A HeLa cells were suspended for 2 h in the presence of varying concentrations of <t>IPA3</t> as indicated, and Ser38 phosphorylation of vimentin was measured as in Fig. A. B HeLa cells suspended for 2 h in the presence or absence of 40 μM IPA3 were analyzed for surface integrin β1 by using flow cytometry. C The mean fluorescence intensities of integrin β1 staining in each condition were normalized against the untreated control and presented as a one-dimensional scatter plot. *, p < 0.05 (paired T test, n = 3). D HeLa and HeLa_VIMKO cells suspended for 24 h in the presence or absence of 40 μM IPA3 were analyzed by flow cytometry as in Fig. A. E Percentages of PI-positive cells in ( D ) are shown. ***, p < 0.0001, n.s.: not significant (one-way ANOVA followed by Tukey multiple-comparison test, n = 3). F Schematic of an in vivo experiment using BLAB/c mice. 1 × 10. cells of 4T1 were injected into the tail vein, and 5 mg/kg IPA3 or DMSO were treated through intraperitoneal injection every day for 14 days. G Representative pictures of lungs from mice treated with control vehicle (top) or IPA3 (bottom) are shown. H The number of metastatic nodules in the lungs in each group was counted and presented as a graph. ***, p < 0.0001 (unpaired T test, n = 5 for each group)
    Ipa 3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ipa3/IPA-3/custom%40hy-15663%4038574695
    Average 94 stars, based on 1 article reviews
    ipa-3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    GNAQ- and GNA11-mutant uveal melanoma cells are sensitive to PAK inhibitors. ( A ). The indicated concentrations of a pan-PAK inhibitor PF3758309 were added to the cultures of 92.1, Mel202 and MP41 uveal melanoma cells. Five days later, cell numbers were compared using the methylene blue staining and extraction method. The values for each cell line were normalized to those in the respective control cultures. Error bars denote standard deviations of quadruplicates. ( B ). 92.1, Mel202 and MP41 uveal melanoma cells were treated with a group I PAK inhibitor IPA3 and the results were analyzed as in A. Half-maximal inhibitory concentrations (IC50) with corresponding 95% confidence intervals (95% CI) are shown.

    Journal: Biomolecules

    Article Title: Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma

    doi: 10.3390/biom15101425

    Figure Lengend Snippet: GNAQ- and GNA11-mutant uveal melanoma cells are sensitive to PAK inhibitors. ( A ). The indicated concentrations of a pan-PAK inhibitor PF3758309 were added to the cultures of 92.1, Mel202 and MP41 uveal melanoma cells. Five days later, cell numbers were compared using the methylene blue staining and extraction method. The values for each cell line were normalized to those in the respective control cultures. Error bars denote standard deviations of quadruplicates. ( B ). 92.1, Mel202 and MP41 uveal melanoma cells were treated with a group I PAK inhibitor IPA3 and the results were analyzed as in A. Half-maximal inhibitory concentrations (IC50) with corresponding 95% confidence intervals (95% CI) are shown.

    Article Snippet: IPA3 was purchased from Selleckchem (S7093) and Cayman Chemical (4759).

    Techniques: Mutagenesis, Staining, Extraction, Control

    MEK inhibitors and PAK inhibitors synergistically suppress uveal melanoma cells. ( A ). 92.1 cells treated with MEKi selumetinib (30 nM), PAKi PF3758309 (4 nM), or the corresponding vehicle (DMSO) control were fixed and visualized by methylene blue staining. ( B – G ). Bliss synergy scores for various MEKi/PAKi combinations in uveal melanoma cell lines. ( B ). 92.1 treated with MEKi selumetinib and PAKi PF3758309. ( C ). 92.1 treated with MEKi selumetinib and PAKi IPA3. ( D ). 92.1 treated with MEKi binimetinib and PAKi IPA3. ( E ). 92.1 treated with MEKi mirdametinib and PAKi IPA3. ( F ). MP41 treated with MEKi binimetinib and PAKi IPA3. ( G ). MP41 treated with MEKi selumetinib and PAKi IPA3. All cultures were analyzed 5 days after the addition of the indicated compounds. Relative survival in ( B – G ) was measured using methylene blue staining and extraction method. Each condition was tested in quadruplicate. SynergyFinder was used to calculate Bliss synergy scores with p -values for each experiment. “SEL”—selumetinib, “BIN”—binimetinib, “MIR”—mirdametinib, “PF”—PF3758309, “IPA”—IPA3.

    Journal: Biomolecules

    Article Title: Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma

    doi: 10.3390/biom15101425

    Figure Lengend Snippet: MEK inhibitors and PAK inhibitors synergistically suppress uveal melanoma cells. ( A ). 92.1 cells treated with MEKi selumetinib (30 nM), PAKi PF3758309 (4 nM), or the corresponding vehicle (DMSO) control were fixed and visualized by methylene blue staining. ( B – G ). Bliss synergy scores for various MEKi/PAKi combinations in uveal melanoma cell lines. ( B ). 92.1 treated with MEKi selumetinib and PAKi PF3758309. ( C ). 92.1 treated with MEKi selumetinib and PAKi IPA3. ( D ). 92.1 treated with MEKi binimetinib and PAKi IPA3. ( E ). 92.1 treated with MEKi mirdametinib and PAKi IPA3. ( F ). MP41 treated with MEKi binimetinib and PAKi IPA3. ( G ). MP41 treated with MEKi selumetinib and PAKi IPA3. All cultures were analyzed 5 days after the addition of the indicated compounds. Relative survival in ( B – G ) was measured using methylene blue staining and extraction method. Each condition was tested in quadruplicate. SynergyFinder was used to calculate Bliss synergy scores with p -values for each experiment. “SEL”—selumetinib, “BIN”—binimetinib, “MIR”—mirdametinib, “PF”—PF3758309, “IPA”—IPA3.

    Article Snippet: IPA3 was purchased from Selleckchem (S7093) and Cayman Chemical (4759).

    Techniques: Control, Staining, Extraction

    Inhibitors of PAK and IMPDH augment MEK inhibitor selumetinib in suppressing the signaling of the MAPK cascade. ( A ). Lysates of 92.1 cells treated for 72 h with selumetinib (30 nM; “SEL”), PF3758309 (4 nM; “PF”) or their combination (“Combo”) were compared to those of untreated control cultures (“UT”; exposed to the vehicle only) by probing with the antibodies for phosphorylated ERK (top), total ERK (middle) and β-actin (bottom). ( B ). Lysates of 92.1 cells treated for 72 h with selumetinib (30 nM; “SEL”), IPA3 (4 µM), or their combination (“Combo”) were analyzed as in A. ( C ). Lysates of 92.1 cells treated for 72 h with selumetinib (30 nM; “SEL”), ribavirin (10 µM; “RBV”) or their combination (“Combo”) were analyzed as in A. ( D ). Three independent experiments performed as in A were analyzed quantitatively, and the intensity of the pERK band was normalized to that of β-actin in each sample. The resulting values from each experiment were further normalized to those in parallel untreated controls. The bars represent averages and the error bars—standard deviations of the three experiments. ( E ). Three independent experiments were performed as in B and analyzed as in D. ( F ). Three independent experiments were performed as in C and analyzed as in D. “*” denotes p < 0.05. “**” denotes p < 0.01. The original Western Blotting images are in the .

    Journal: Biomolecules

    Article Title: Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma

    doi: 10.3390/biom15101425

    Figure Lengend Snippet: Inhibitors of PAK and IMPDH augment MEK inhibitor selumetinib in suppressing the signaling of the MAPK cascade. ( A ). Lysates of 92.1 cells treated for 72 h with selumetinib (30 nM; “SEL”), PF3758309 (4 nM; “PF”) or their combination (“Combo”) were compared to those of untreated control cultures (“UT”; exposed to the vehicle only) by probing with the antibodies for phosphorylated ERK (top), total ERK (middle) and β-actin (bottom). ( B ). Lysates of 92.1 cells treated for 72 h with selumetinib (30 nM; “SEL”), IPA3 (4 µM), or their combination (“Combo”) were analyzed as in A. ( C ). Lysates of 92.1 cells treated for 72 h with selumetinib (30 nM; “SEL”), ribavirin (10 µM; “RBV”) or their combination (“Combo”) were analyzed as in A. ( D ). Three independent experiments performed as in A were analyzed quantitatively, and the intensity of the pERK band was normalized to that of β-actin in each sample. The resulting values from each experiment were further normalized to those in parallel untreated controls. The bars represent averages and the error bars—standard deviations of the three experiments. ( E ). Three independent experiments were performed as in B and analyzed as in D. ( F ). Three independent experiments were performed as in C and analyzed as in D. “*” denotes p < 0.05. “**” denotes p < 0.01. The original Western Blotting images are in the .

    Article Snippet: IPA3 was purchased from Selleckchem (S7093) and Cayman Chemical (4759).

    Techniques: Control, Western Blot

    Effects of inhibiting vimentin S38 phosphorylation on metastasis. A HeLa cells were suspended for 2 h in the presence of varying concentrations of IPA3 as indicated, and Ser38 phosphorylation of vimentin was measured as in Fig. A. B HeLa cells suspended for 2 h in the presence or absence of 40 μM IPA3 were analyzed for surface integrin β1 by using flow cytometry. C The mean fluorescence intensities of integrin β1 staining in each condition were normalized against the untreated control and presented as a one-dimensional scatter plot. *, p < 0.05 (paired T test, n = 3). D HeLa and HeLa_VIMKO cells suspended for 24 h in the presence or absence of 40 μM IPA3 were analyzed by flow cytometry as in Fig. A. E Percentages of PI-positive cells in ( D ) are shown. ***, p < 0.0001, n.s.: not significant (one-way ANOVA followed by Tukey multiple-comparison test, n = 3). F Schematic of an in vivo experiment using BLAB/c mice. 1 × 10. cells of 4T1 were injected into the tail vein, and 5 mg/kg IPA3 or DMSO were treated through intraperitoneal injection every day for 14 days. G Representative pictures of lungs from mice treated with control vehicle (top) or IPA3 (bottom) are shown. H The number of metastatic nodules in the lungs in each group was counted and presented as a graph. ***, p < 0.0001 (unpaired T test, n = 5 for each group)

    Journal: BMC Biology

    Article Title: Vimentin-mediated buffering of internal integrin β1 pool increases survival of cells from anoikis

    doi: 10.1186/s12915-024-01942-w

    Figure Lengend Snippet: Effects of inhibiting vimentin S38 phosphorylation on metastasis. A HeLa cells were suspended for 2 h in the presence of varying concentrations of IPA3 as indicated, and Ser38 phosphorylation of vimentin was measured as in Fig. A. B HeLa cells suspended for 2 h in the presence or absence of 40 μM IPA3 were analyzed for surface integrin β1 by using flow cytometry. C The mean fluorescence intensities of integrin β1 staining in each condition were normalized against the untreated control and presented as a one-dimensional scatter plot. *, p < 0.05 (paired T test, n = 3). D HeLa and HeLa_VIMKO cells suspended for 24 h in the presence or absence of 40 μM IPA3 were analyzed by flow cytometry as in Fig. A. E Percentages of PI-positive cells in ( D ) are shown. ***, p < 0.0001, n.s.: not significant (one-way ANOVA followed by Tukey multiple-comparison test, n = 3). F Schematic of an in vivo experiment using BLAB/c mice. 1 × 10. cells of 4T1 were injected into the tail vein, and 5 mg/kg IPA3 or DMSO were treated through intraperitoneal injection every day for 14 days. G Representative pictures of lungs from mice treated with control vehicle (top) or IPA3 (bottom) are shown. H The number of metastatic nodules in the lungs in each group was counted and presented as a graph. ***, p < 0.0001 (unpaired T test, n = 5 for each group)

    Article Snippet: 1.5 × 10 5 cells suspended on a poly-HEMA-coated surface for 0 to 24 h in the presence or absence of 20 ~ 40 μM RGDS peptides (RnD system, 3498–10), 10 ~ 40 μM IPA3 (Sigma, I2285), or 10 μM withaferin A (APExBio, B7199).

    Techniques: Flow Cytometry, Fluorescence, Staining, Control, Comparison, In Vivo, Injection